LABORATORY CP OF AMER HLDGS's gross profit margin for the fourth quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased. LABORATORY CP OF AMER HLDGS has average liquidity. Currently, the Quick Ratio is 1.43 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 13.21% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||1512.7||1437.0|
|Net Income ($mil)||119.6||126.3|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||580.0||404.0|
|Total Assets ($mil)||7301.8||6965.9|
|Total Debt ($mil)||3029.8||3000.4|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||38.57||39.28|
|Return on Assets||7.0||8.23|
|Return on Equity||18.12||23.03|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||84.9||85.7|
|Div / share||0.0||0.0|
|Book value / share||33.22||29.07|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1472325.0||994221.0|
BUY. The current P/E ratio indicates a significant discount compared to an average of 71.34 for the Health Care Providers & Services industry and a value on par with the S&P 500 average of 19.92. To use another comparison, its price-to-book ratio of 3.75 indicates a premium versus the S&P 500 average of 2.81 and a discount versus the industry average of 4.25. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly above the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, LABORATORY CP OF AMER HLDGS proves to trade at a discount to investment alternatives within the industry.
|LH 21.00||Peers 71.34||LH 14.30||Peers 14.58|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
LH is trading at a significant discount to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
LH is trading at a valuation on par to its peers.
|LH 14.48||Peers 19.09||LH 0.73||Peers 2.33|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
LH is trading at a discount to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
LH trades at a significant discount to its peers.
|LH 3.75||Peers 4.25||LH -4.97||Peers -13.75|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
LH is trading at a discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
LH is expected to have an earnings growth rate that significantly exceeds its peers.
|LH 1.76||Peers 0.88||LH 3.50||Peers 14.20|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
LH is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
LH significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV